CIOReview Names Flagship Company of the Year
CIOReview named Flagship Biosciences “Company of the Year,” as part of the publication’s 2018 20 Most Promising Pharma & Life Sciences Tech Solution Providers industry
POSTER: Using Artificial Intelligence to Predict Response to Immunotherapy
Key Concepts: Pathological interpretations applied to PD-L1 IHC as a response biomarker are becoming more complex, going beyond simple tumor proportion score (TPS) and requiring
POSTER: Pathology AI (Artificial Intelligence)
Deep learning has created a hype about artificial intelligence (AI) and healthcare AI. Flagship Biosciences has been developing a pathology AI system over the last
Intelligent Pharma Partners: Pathology AI Needs a New Business Model
The true barrier to artificial intelligence (AI) in pathology is not the technology; it’s the business model. Flagship Biosciences believes that the true opportunity for
2018 Global AI-based Pathology Solutions in Immuno-oncology Technology Innovation Award
Based on its recent analysis of the global market for artificial intelligence (AI)-based pathology solutions in immuno-oncology (I-O), Frost & Sullivan recognizes Flagship Biosciences, Inc.
Validation of a Muscle-Specific Tissue Image-Analysis Tool for Quantitative Assessment of Dystrophin Staining in Frozen Muscle Biopsies
Key Concepts: Flagship Biosciences’ MuscleMap algorithm that supports therapeutic development for DMD, a fatal neuromuscular disease, has been validated to be as effective as manual
